Global Market for Hepatitis B Diagnostic Tests to Expand at a 6.5% CAGR through 2033, reaching US$ 1,744.26 Million | Future Market Insights Inc.
Cutting-edge hepatitis B diagnostic technology advances early detection, driving preventative healthcare and regional demand in the US.
NEWARK, Del, Oct. 10, 2023 (GLOBE NEWSWIRE) — The global hepatitis B diagnostic tests market is anticipated to reach a valuation of US$ 872.5 million in 2023, driven by health screenings and government initiatives. This trend is expected to create new opportunities for the global market, leading to a projected CAGR of 6.5% between 2023 and 2033. It is estimated to gain a valuation of approximately US$ 1,744.26 million by 2033.
Continuous advancements in diagnostic technology substantially influence the market for hepatitis B diagnostic tests. Developing assay methods such as enzyme immunoassays and nucleic acid testing has improved the accuracy of tests, sensitivity, and specificity.
The most frequent cause of liver disease and cancer is hepatitis B. The relevance of liver health has led to an increase in people seeking preventative healthcare, especially those with risk factors, including a genetic history of hepatitis B or particular behaviors. Regular hepatitis B testing enables early detection and treatment, and this can help prevent issues and liver damage. The regional demand is increasing across the United States because of the emphasis on preventative care and living well.
Request a Sample Copy of the Hepatitis B Diagnostic Tests Market Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-1332
Key Takeaways from the Hepatitis B Diagnostic Tests Market Study
- The market for hepatitis B diagnostic tests expanded at a CAGR of 4.5% from 2018 to 2022.
- The Hepatitis B Diagnostic Tests market in the United States is expected to surpass 34.7% market share in 2023.
- It is predicted that China would take 23.2% of the worldwide market for hepatitis B diagnostic tests in 2023.
- By the end of 2023, the market for hepatitis B diagnostic tests in Japan will hold 7.1% of the global market share.
- By 2023, it is expected that the market for hepatitis B diagnostic tests in France will increase by 8%.
- By 2023, the Hepatitis B Diagnostic Tests market in the United Kingdom is anticipated to have a 7.8% market share.
- In 2023, it is anticipated that the market share held by enzyme immunoassay kits will reach 71.90%.
- The hospitals segment will expand quickly at a 6.2% CAGR throughout the projection period.
“The hepatitis B diagnostic tests are promoted through public health programs, increasing liver exams, and healthcare marketing, which raises awareness and diagnoses rates,” remarks Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Competitive Landscape of Hepatitis B Diagnostic Tests Market:
Manufacturers frequently explore new geographical areas to increase their market presence. With healthcare organizations and providers all across the world, they create distribution networks and partnerships. Manufacturers can access untapped client bases by diversifying into new markets and areas with a high hepatitis B incidence.
To make sure that their goods adhere to local norms and laws, businesses may also apply for regulatory licenses and certifications in other nations.
Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1332
Top 10 Players in the Hepatitis B Diagnostic Tests Market are:
- Bio-Rad Laboratories, Inc.
- DiaSorin S.p.A.
- Abbott Laboratories
- Meridian Bioscience
- bioMérieux SA Inc.
- Vista Diagnostics International
- Biogate Laboratories Ltd.
- J.Mitra & Co. Ltd.
- Siemens Medical Solutions USA, Inc.
- General Biologicals Corporation
Product Portfolio of Hepatitis B Diagnostic Tests Market:
- A healthcare corporation with a wide range of services, Abbott Laboratories has been involved in the creation of medicines, notably antiviral drugs. They have created medications in the past that are used to treat chronic hepatitis B. One such instance is the drug “Hepsera” (generic name: adefovir dipivoxil), that was used in some individuals to prevent the reproduction of the hepatitis B virus.
- “Viread,” made by Gilead Sciences, Inc., is one of the treatments for hepatitis B that is often used. Tenofovir disoproxil fumarate (TDF), the active component of Viread, is an antiviral drug intended to prevent the hepatitis B virus (HBV) from replicating in people with chronic hepatitis B infection.
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/1332
More Valuable Insights Available:
Future Market Insights offers an unbiased analysis of the global hepatitis B diagnostic tests market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the hepatitis B diagnostic tests market, the market is segmented based on product type (enzyme immunoassay kits, point-of-care testing kits), end user (hospitals, clinics, diagnostic centers, home care), end user (hospitals, clinics, diagnostic centers, home care) and across seven major regions (North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia, and Middle East & Africa (MEA)).
Segmentation Analysis of the Hepatitis B Diagnostic Tests Market:
By Product Type:
- Enzyme Immunoassay Kits
- Hepatitis B Surface Antigen Test
- Anti-Hepatitis B Surface Antibody Test
- Anti-Hepatitis B Core Antibody Test
- Point-of-Care Testing Kits
- Strips
- Cassettes/Cards
By End User:
- Hospitals
- Clinics
- Diagnostic Centers
- Home Care
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- The Middle East & Africa
About the Healthcare Division at Future Market Insights
The healthcare domain at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with the objective of providing authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 billion+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Have a Look at Related Reports of the Healthcare Domain:
Diagnostic Imaging Services Market: Diagnostic imaging is a process of imaging the human body with the help of various imaging services. These services includes several technologies, techniques, and equipment’s to monitor, diagnose, screen, and treat medical conditions for effective medical intervention.
Portable Medical Devices Market: is projected to expand at a CAGR of 10.7% during the forecast period. The market is estimated to generate market revenue of US$ 163.84 billion by 2033.
Diagnostic Exosome Biomarkers Market: is anticipated to reach US$ 196.8 million by 2023. Diagnostic exosome biomarkers sales are anticipated to expand at a significant CAGR of 16.3% between 2023 and 2033.
Diagnostic Imaging Markers Market: A diagnostic imaging marker is a biomarker or a biologic feature that is detectable in an image. This image is relevant to the diagnosis of a patient for a certain disease.
Diagnostic X-Ray System Market: is expected to enjoy a valuation of US$ 11.30 Billion by the end of the year 2022, and further expand at a CAGR rate of 6.1% to reach a valuation of ~US$ 20.46 Billion by the year 2032.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
